CompletedNot Applicable

Probiotics for Liver Cirrhosis With Portal Hypertension

Taiwan49 participantsStarted 2012-04

Plain-language summary

Recent studies indicate that probiotics can stimulate intestinal immunity and tighten the junctions of epithelial cells. By these ways, probiotics can reduce bacterial translocation; hence, they can ameliorate systemic inflammatory status. Because cirrhotic patients with portal hypertension often suffer from infections from intestinal flora, the investigators speculate that probiotics will be beneficial to those patients.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with history of complications related to liver cirrhosis, including hepatic encephalopathy, variceal bleeding, and spontaneous bacterial peritonitis
✓. Patients with evidences of portal hypertension, such as hepatosplenomegaly, thrombocytopenia (\< 100,000/ml)

Exclusion criteria

✕. Active infection
✕. Dialysis patients, myocardial infarction, life-threatening cardiac arrythmia and stroke
✕. Hepatocellular carcinoma with life expectancy \< 6 months
✕. Portal vein thrombosis
✕. in hepatic encephalopathy or liver function ALT \> 3 x UNL, T-bilirubin \> 4.0 mg/dL
✕. GI tract bleeding in recent 1 weeks
✕. Drug abuser
✕. No informed consent

What they're measuring

Admission Due to Complications Related to Portal Hypertension

Timeframe: 8 weeks

Trial details

NCT IDNCT01598064

SponsorPo-Lin Chen, MD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-08

Results submitted2014-07-14

View on ClinicalTrials.gov More Liver Cirrhosis trials